Yes, Pfizer should buy Bristol-Myers Squibb instead of AstraZeneca, but it won't.
Big pharma's been in a funk over the recent past with the patent cliff and the recession, but these three stocks have delivered for investors.
BioCryst, Durata, Bristol-Myers Squibb, and Incyte could all loom large in health care headlines today. Here’s why.
How breakthrough designation for a new multiple myeloma drug helps three drug companies.
Check out which stocks one of the world's most successful hedge funds recently bought and why.
Big pharma's home to many great dividends, but is Bristol-Myers Squibb's yield the best bet for your money?
Cancer research as a team sport.
A quickly-soaring market valuation is hiding a realistic interpretation of Repligen's P/E ratio after the end of a royalty stream from Bristol-Myers Squibb.
Top stories in health care and biotech.
Three leading names take big hits on what turned out to be a horrid day for investors, as Bristol-Myers, National Bank of Greece, and Alliant Techsystems all fall in big ways